Fluoroquinolone Resistance Mutations in the DNA Topoisomerase II Genes of Viridans Group Streptococci Clinical Isolates

被引：0
|
作者：
Delia Balas
Irene González
Marios Georgiou
Fernando Alcaide
Josefina Liñares
Adela G. De La Campa
机构：
[1] Instituto de Salud Carlos III,Unidad de Genética Bacteriana (CSIC), Centro Nacional de Biologia Fundamental
[2] University of Greenwich,undefined
[3] Hospital de Belltvitge,undefined
来源：
Drugs | 1999年 / 58卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：125 / 127
页数：2
相关论文
共 50 条
  • [1] Fluoroquinolone resistance mutations in the DNA topoisomerase II genes of viridans group streptococci clinical isolates
    Balas, D
    González, I
    Georgiou, M
    Alcaide, F
    Liñares, J
    De la Campa, AG
    DRUGS, 1999, 58 (Suppl 2) : 125 - 127
  • [2] Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci
    González, I
    Georgiou, M
    Alcaide, F
    Balas, D
    Liñares, J
    De la Campa, AG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2792 - 2798
  • [3] Fluoroquinolone resistance associated with target mutations and active efflux in orophalyngeal colonizing isolates of viridans group streptococci
    Guerin, F
    Varon, E
    Hoï, AB
    Gutmann, L
    Podglajen, I
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) : 2197 - 2200
  • [4] Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci
    Ferrándiz, MJ
    Oteo, J
    Aracil, B
    Gómez-Garcés, JL
    de la Campa, AG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2520 - 2523
  • [5] Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance
    Bast, DJ
    Low, DE
    Duncan, CL
    Kilburn, L
    Mandell, LA
    Davidson, RJ
    de Azavedo, JCS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) : 3049 - 3054
  • [6] Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae
    Millichap, JJ
    Pestova, E
    Siddiqui, F
    Noskin, GA
    Peterson, LR
    JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) : 2719 - 2721
  • [7] Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants
    Ehrmann, Elodie
    Jolivet-Gougeon, Anne
    Bonnaure-Mallet, Martine
    Fosse, Thierry
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (08) : 2208 - 2212
  • [8] Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants
    Ricci, V
    Peterson, ML
    Rotschafer, JC
    Wexler, H
    Piddock, LJV
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) : 1344 - 1346
  • [9] Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates
    Bansal, Sandhya
    Tandon, Vibha
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (03) : 253 - 255
  • [10] Fluoroquinolone resistance among invasive viridans group streptococci and Streptococcus bovis isolated in Spain
    Rodriguez-Avial, Iciar
    Rodriguez-Avial, Carmen
    Culebras, Esther
    Picazo, Juan J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (04) : 478 - 480
12345